ARTIMPLANT AB's INTERIM REPORT JANUARY 1 - JUNE 30, 2004

ARTIMPLANT AB's INTERIM REPORT JANUARY 1 - JUNE 30, 2004 INCREASED SALES EFFORTS AND CONTINUED STRONG CASH POSITION - Artimplant´s net sales for the 6 month period reached SEK 1.0 million (SEK 1.2 million) - Losses after tax amounted to SEK -13.3 million (SEK -11.2 million) - The result per share amounted to SEK -0.35 (SEK -0.52) - Liquid funds at the end of the period amounted to SEK 63.8 million - Artelon TMC Spacer marketing activities have commenced in the Nordic countries DEVELOPMENTS AFTER THE END OF THE PERIOD - The test sales of Artelon ACL Augmentation Device in the United Kingdom has expired For more information, contact: Tord Lendau, CEO, +46 31 746 5600, +46 708 369 403, tord.lendau@artimplant.se Jonas Ström, CFO, +46 31 746 5654, +46 703 016 854, jonas.strom@artimplant.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/08/27/20040827BIT20280/wkr0001.pdf The full report